Press Releases

BrainStorm CEO to Present at the Phacilitate Cell & Gene Therapy World Conference 2017 in Miami

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Jan. 17, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will give a presentation entitled "NurOwn® – ground breaking treatment for ALS and other neurodegenerative diseases", during the Biotech Showcase at the Phacilitate Cell & Gene Therapy World 2017 Conference. The session will be held on January 18, 2017 at the Hyatt Regency in Miami, Florida. Mr. Lebovits will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Phacilitate Cell & Gene Therapy World 2017


Wednesday, January 18


10.50 am EST


Hyatt Regency Miami


The Cell & Gene Therapy World 2017 conference runs from January 17-20, 2017, at the Hyatt Regency in Miami, Florida. For more information, refer to

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at


Uri Yablonka
Chief Operating Officer
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188

Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979


To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds